Compare Deere & Company (DE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs TG Therapeutics Inc — how do they compare? Deere & Company trades at $620.93 (market cap $175.95B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Deere & Company is far larger — about 21.6× TG Therapeutics Inc's market cap, and Deere & Company pays a 0.99% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and TG Therapeutics Inc for 16 Days on average.
| DE | TGTX | |
|---|---|---|
Market Cap | $175.95B | $8.16B |
Volume | 1,387,231 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $709.48 | $59.06 |
52-Week Low | $439.11 | $26.94 |
Typical Hold Time | 75 Days | 16 Days |
Enterprise Value | $229.85B | $8.37B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) is trading at $620.93, down 5.47% today, reflecting recent market pressure despite a strong earnings beat history. The stock shows bearish technical signals but maintains solid profitability with a 10.39% net margin and 18.4% ROE. Recent news highlights the company's AI initiatives and institutional interest, though revenue has declined from 2023 peaks. Current levels are near key support at $623, with the consensus price target of $731.20 suggesting upside potential if fundamentals stabilize.
The outlook for DE hinges on agricultural cycle recovery and execution of technology-driven growth. Near-term risks include cyclical demand weakness and elevated debt, but analyst consensus leans bullish with 43% buy ratings. The stock offers a dividend yield supported by cash flow, yet investors face volatility from macroeconomic and sector-specific headwinds.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
